Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase? [electronic resource]
Producer: 20130723Description: 391-4 p. digitalISSN:- 1600-0641
- Antiviral Agents -- administration & dosage
- Cost-Benefit Analysis
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Genotype
- Hepacivirus -- enzymology
- Hepatitis C -- drug therapy
- Humans
- Interferon-alpha -- administration & dosage
- Oligopeptides -- administration & dosage
- Polyethylene Glycols -- administration & dosage
- Proline -- administration & dosage
- Protease Inhibitors -- administration & dosage
- Recombinant Proteins -- administration & dosage
- Ribavirin -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.